3 terminated. 3 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Terminated 3 |
| Phase 1 | 2 | Terminated 2 |
Follow Follicular Lymphoma (FL): new trials by email Literature Review of Follicular Lymphoma (FL) trials Research Report on Follicular Lymphoma (FL)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of MS-553 in Patients With Relapsed or Refractory B-cell Lymphoma MS-553 - Relapsed or Refractory B-cell Lymphoma, Diffuse Large B-cell Lymphoma (DLBCL) | Phase 1 / Phase 2 | Terminated | MingSight Pharmaceuticals, Inc | 8 | 2023-02-06 | 2024-07-18 |
| Zandelisib (ME-401) in Subjects With Follicular Lymphoma or Marginal Zone Lymphoma After Failure of Two or More Prior Therapies (TIDAL) Zandelisib (ME-401) - Follicular Lymphoma (FL), Non Hodgkin Lymphoma | Phase 2 | Terminated | MEI Pharma, Inc. | 169 | 2019-06-25 | 2024-12-31 |
| A Study to Assess Long-term Safety of Tazemetostat in Adult Participants of All Ages With Any Disease Treated With Tazemetostat in a Previous Clinical Study Tazemetostat - Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL) | Phase 1 / Phase 2 | Terminated | Epizyme, Inc. | 58 | 2016-08-30 | 2026-10-28 |
Lymphoma, Follicular (3) · Lymphoma, B-Cell, Marginal Zone (2) · Lymphoma, Large B-Cell, Diffuse (2) · Lymphoma, Non-Hodgkin (2) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Lymphoma, B-Cell (1) · Lymphoma, Mantle-Cell (1) · Mesothelioma (1) · Recurrence (1) · Sarcoma (1) · Sarcoma, Synovial (1)
Hemic and Lymphatic Diseases (3) · Immune System Diseases (3) · Immunoproliferative Disorders (3) · Lymphatic Diseases (3) · Lymphoma (3) · Lymphoproliferative Disorders (3) · Neoplasms (3) · Neoplasms by Histologic Type (3) · Lymphoma, B-Cell (2) · Adenoma (1) · Chronic Disease (1) · Disease Attributes (1) · Hematologic Diseases (1) · Leukemia (1) · Leukemia, B-Cell (1)
ME-401 (1) · tazemetostat (1)
Epizyme, Inc. (1) · MEI Pharma, Inc. (1) · MingSight Pharmaceuticals, Inc (1)
Australia (2) · Belgium (2) · France (2) · Poland (2) · United Kingdom (2) · United States (2) · Austria (1) · China (1) · Germany (1) · Italy (1) · New Zealand (1) · South Korea (1) · Spain (1) · Switzerland (1) · Taiwan (1)
2015 (1), 2018 (1), 2023 (1)